Trump's Most-Favored-Nation Drug Pricing Faces Legal Hurdles
President Trump's initiative to implement a most-favored-nation (MFN) clause for prescription drug pricing aims to align U.S. drug costs with those in other high-income countries. The administration projects that this could save $529 billion over the next decade, according to a White House report.
Trump has publicly stated that the MFN clause would ensure the U.S. pays no more than other countries for the same drugs, potentially reducing prices by up to 70%. However, this unilateral approach may face significant legal challenges under U.S. trade law.
The U.S. Department of Justice's Office of Legal Counsel has previously noted that extending trade benefits, such as those proposed under the MFN clause, requires explicit Congressional authorization. This legal framework could impede the broad application of Trump's drug-pricing strategy without legislative support.
Despite these potential hurdles, the Trump administration has secured voluntary MFN agreements with 17 major pharmaceutical manufacturers. These agreements are part of a prospective MFN structure that aims to price new drugs in the U.S. similarly to other high-income nations.